TXG logo

10x Genomics, Inc. (TXG) EBITDA

Annual EBITDA:

-$133.99M+$71.12M(+34.68%)
December 31, 2024

Summary

  • As of today, TXG annual EBITDA is -$133.99 million, with the most recent change of +$71.12 million (+34.68%) on December 31, 2024.
  • During the last 3 years, TXG annual EBITDA has fallen by -$109.39 million (-444.78%).
  • TXG annual EBITDA is now -883.40% below its all-time high of -$13.63 million, reached on December 31, 2017.

Performance

TXG EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTXGincome statement metrics

Quarterly EBITDA:

-$19.99M-$19.07M(-2065.87%)
September 30, 2025

Summary

  • As of today, TXG quarterly EBITDA is -$19.99 million, with the most recent change of -$19.07 million (-2065.87%) on September 30, 2025.
  • Over the past year, TXG quarterly EBITDA has increased by +$10.74 million (+34.96%).
  • TXG quarterly EBITDA is now -753.51% below its all-time high of $3.06 million, reached on December 31, 2020.

Performance

TXG Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTXGincome statement metrics

TTM EBITDA:

-$98.54M+$10.74M(+9.83%)
September 30, 2025

Summary

  • As of today, TXG TTM EBITDA is -$98.54 million, with the most recent change of +$10.74 million (+9.83%) on September 30, 2025.
  • Over the past year, TXG TTM EBITDA has increased by +$34.84 million (+26.12%).
  • TXG TTM EBITDA is now -652.59% below its all-time high of -$13.09 million, reached on September 30, 2021.

Performance

TXG TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTXGincome statement metrics

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

TXG EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year+34.7%+35.0%+26.1%
3Y3 Years-444.8%+37.3%+23.5%
5Y5 Years-541.5%-3.0%-30.5%

TXG EBITDA Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-444.8%+34.7%-2065.9%+61.2%at high+40.4%
5Y5-Year-541.5%+73.9%-753.5%+63.4%-652.6%+40.4%
All-TimeAll-Time-883.4%+73.9%-753.5%+73.0%-652.6%+40.4%

TXG EBITDA History

DateAnnualQuarterlyTTM
Sep 2025
-
-$19.99M(-2065.9%)
-$98.54M(+9.8%)
Jun 2025
-
-$923.00K(+97.6%)
-$109.29M(+21.5%)
Mar 2025
-
-$38.61M(+1.0%)
-$139.20M(+6.3%)
Dec 2024
-$133.99M(+34.7%)
-$39.02M(-26.9%)
-$148.49M(-11.3%)
Sep 2024
-
-$30.73M(+0.3%)
-$133.38M(+7.8%)
Jun 2024
-
-$30.84M(+35.6%)
-$144.62M(+12.5%)
Mar 2024
-
-$47.90M(-100.4%)
-$165.26M(-2.8%)
Dec 2023
-$205.11M(-59.6%)
-$23.90M(+43.0%)
-$160.73M(-6.1%)
Sep 2023
-
-$41.97M(+18.5%)
-$151.45M(-7.1%)
Jun 2023
-
-$51.48M(-18.7%)
-$141.36M(+2.2%)
Mar 2023
-
-$43.37M(-196.6%)
-$144.55M(-7.1%)
Dec 2022
-$128.49M(-422.4%)
-$14.62M(+54.1%)
-$134.94M(-4.7%)
Sep 2022
-
-$31.88M(+41.7%)
-$128.82M(-22.1%)
Jun 2022
-
-$54.67M(-61.9%)
-$105.54M(-92.4%)
Mar 2022
-
-$33.76M(-296.9%)
-$54.86M(-122.5%)
DateAnnualQuarterlyTTM
Dec 2021
-$24.59M(+95.2%)
-$8.51M(+1.1%)
-$24.66M(-88.3%)
Sep 2021
-
-$8.60M(-115.6%)
-$13.09M(+45.2%)
Jun 2021
-
-$3.99M(-12.2%)
-$23.90M(+56.2%)
Mar 2021
-
-$3.56M(-216.3%)
-$54.54M(+19.1%)
Dec 2020
-$513.77M(-2359.7%)
$3.06M(+115.8%)
-$67.37M(+10.8%)
Sep 2020
-
-$19.41M(+44.0%)
-$75.53M(-19.6%)
Jun 2020
-
-$34.63M(-111.2%)
-$63.17M(-68.4%)
Mar 2020
-
-$16.39M(-221.9%)
-$37.51M(-63.1%)
Dec 2019
-$20.89M(+80.3%)
-$5.09M(+27.8%)
-$23.00M(+74.9%)
Sep 2019
-
-$7.05M(+21.4%)
-$91.81M(+6.9%)
Jun 2019
-
-$8.97M(-376.7%)
-$98.58M(-10.0%)
Mar 2019
-
-$1.88M(+97.5%)
-$89.61M(-2.1%)
Dec 2018
-$106.08M(-678.6%)
-$73.90M(-434.7%)
-$87.73M(-534.7%)
Sep 2018
-
-$13.82M
-$13.82M
Dec 2017
-$13.63M
-
-

FAQ

  • What is 10x Genomics, Inc. annual EBITDA?
  • What is the all-time high annual EBITDA for 10x Genomics, Inc.?
  • What is 10x Genomics, Inc. annual EBITDA year-on-year change?
  • What is 10x Genomics, Inc. quarterly EBITDA?
  • What is the all-time high quarterly EBITDA for 10x Genomics, Inc.?
  • What is 10x Genomics, Inc. quarterly EBITDA year-on-year change?
  • What is 10x Genomics, Inc. TTM EBITDA?
  • What is the all-time high TTM EBITDA for 10x Genomics, Inc.?
  • What is 10x Genomics, Inc. TTM EBITDA year-on-year change?

What is 10x Genomics, Inc. annual EBITDA?

The current annual EBITDA of TXG is -$133.99M

What is the all-time high annual EBITDA for 10x Genomics, Inc.?

10x Genomics, Inc. all-time high annual EBITDA is -$13.63M

What is 10x Genomics, Inc. annual EBITDA year-on-year change?

Over the past year, TXG annual EBITDA has changed by +$71.12M (+34.68%)

What is 10x Genomics, Inc. quarterly EBITDA?

The current quarterly EBITDA of TXG is -$19.99M

What is the all-time high quarterly EBITDA for 10x Genomics, Inc.?

10x Genomics, Inc. all-time high quarterly EBITDA is $3.06M

What is 10x Genomics, Inc. quarterly EBITDA year-on-year change?

Over the past year, TXG quarterly EBITDA has changed by +$10.74M (+34.96%)

What is 10x Genomics, Inc. TTM EBITDA?

The current TTM EBITDA of TXG is -$98.54M

What is the all-time high TTM EBITDA for 10x Genomics, Inc.?

10x Genomics, Inc. all-time high TTM EBITDA is -$13.09M

What is 10x Genomics, Inc. TTM EBITDA year-on-year change?

Over the past year, TXG TTM EBITDA has changed by +$34.84M (+26.12%)
On this page